FDA 宣布启动 EAST 计划,以新方法开展药品质量抽样与检测
FDA Introduces New Approach to Drug Quality Sampling and Testing
FDA 宣布启动 EAST(Enhanced Approach for Sampling and Testing)计划,将现代筛查技术与传统检测方法结合,用于监测美国市场上的药品质量。该计划将检测来自零售药房和批发分销商的药品样本,项目包括鉴别、纯度和效价,并把检测扩展到更多生产商、治疗类别和地域。FDA 表示检测结果将用于识别潜在质量风险、判断是否需要采取监管行动并规划未来检查。
材料说明 EAST 将现代筛查与传统检测方法结合并扩大抽样覆盖范围,可用于了解 FDA 药品质量监测方式的调整。
[11/18/2026] The U.S. Food and Administration today announced the launch of its Enhanced Approach for Sampling and Testing (EAST) initiative, a new approach to monitoring the quality of drug products available to Americans.
EAST combines modern screening techniques with traditional testing methods to help FDA test more drugs and identify potential quality issues faster. The initiative expands the agency’s testing efforts to cover more manufacturers, therapeutic classes, and geographic regions, both in the U.S. and abroad.
“The EAST initiative gives us an enhanced way to monitor drug quality across an increasingly complex global supply chain,” said Dr. Michael Kopcha, PhD, RPh, Director of FDA’s Office of Pharmaceutical Quality. “With this approach, we can gather more information about drug quality and make decisions to help protect public health.”
As part of the initiative, the FDA will test drug samples from retail pharmacies and wholesale distributors. The testing looks at key factors, including identity, purity, and potency, to see if the drugs meet established quality standards. The initiative will help the agency identify potential quality issues faster.
The FDA will use the test results to identify potential drug quality risks, decide if regulatory action is needed, and plan future inspections. EAST builds on the agency’s existing testing efforts and gives the FDA an enhanced way to monitor the quality of drugs sold in the U.S.
For more information about EAST, visit FDA’s Enhanced Approach for Sampling and Testing.
来源:FDA 官方药品与生物制品信息 · fda.gov